Based in Schlieren, Switzerland, NovaGo was founded in 2015 by ETH Zurich neuroscientist, Martin Schwab, to develop therapeutics that target the growth guidance protein, Nogo-A. The company is ...
Schwab identified Nogo-A as a key inhibitor of axonal growth. Since then he has founded NovaGo Therapeutics to pursue the development of regenerative therapies for CNS disorders. A strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback